Franziska A. V. Elsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Franziska A. V. Elsen has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Stephan Axel Sieber
Center for Functional Protein Assemblies (CPA) Department of Bioscience, TUM School of Natural Sciences Technical University of Munich (TUM) Garching Germany
2 shared publications - Andrew Ji
Research Service, Atlanta VA Medical Center
1 shared publication Carter U. Brzezinski
Department of Chemistry, Emory University
1 shared publicationDietmar H. Pieper
Helmholtz Centre for Infection Research, Microbial Interactions and Processes, Inhoffenstraße 7, 38124 Braunschweig, Germany
1 shared publication- Dietrich Mostert
Center for Functional Protein Assemblies, Department of Bioscience, TUM School of Natural Sciences, Technical University of Munich, Ernst-Otto-Fischer-Straße 8, 85748 Garching, Germany
1 shared publication - Dominik Schum
TUM School of Natural Sciences, Department of Bioscience, Center for Functional Protein Assemblies (CPA), Chair of Organic Chemistry II, Technical University of Munich, Ernst-Otto-Fischer Strasse 8, Garching bei München, 85748, Germany
1 shared publication
Latest Publications
- Open Access
- 10 June 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (24)
Repurposing a drug to punish carbapenem-resistant Acinetobacter baumannii
The OXA β-lactamases in Acinetobacter baumannii represent a primary mechanism for resistance to the carbapenems, a class of antibiotics that represent a last line for treatment. In a screen of an U.S. Food and Drug Administration (FDA)-approved drug library, we identified fendiline, a calcium channel blocker, had significantly more antimicrobial activity against OXA-23 expressing cells. Genetic and proteomic studies revealed that fendiline inhibited the essential lipoprotein trafficking pathway (Lol) in both A. baumannii (LolFD) and Escherichia coli (LolCDE). We demonstrate that OXA-23 is an outer membrane lipoprotein and its overexpression resulted in increased lethality in lolFD- depleted A. baumannii . Our results indicate that overexpression of the OXA-23 β-lactamase in A. baumannii stresses normal lipoprotein trafficking, which makes these cells more susceptible to fendiline. Overall, our data reveal a link between carbapenem resistance and the Lol pathway, which can be leveraged for new drug development.
- 10 June 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (24)
Open AccessRepurposing a drug to punish carbapenem-resistant Acinetobacter baumannii
The OXA β-lactamases in Acinetobacter baumannii represent a primary mechanism for resistance to the carbapenems, a class of antibiotics that represent a last line for treatment. In a screen of an U.S. Food and Drug Administration (FDA)-approved drug library, we identified fendiline, a calcium channel blocker, had significantly more antimicrobial activity against OXA-23 expressing cells. Genetic and proteomic studies revealed that fendiline inhibited the essential lipoprotein trafficking pathway (Lol) in both A. baumannii (LolFD) and Escherichia coli (LolCDE). We demonstrate that OXA-23 is an outer membrane lipoprotein and its overexpression resulted in increased lethality in lolFD- depleted A. baumannii . Our results indicate that overexpression of the OXA-23 β-lactamase in A. baumannii stresses normal lipoprotein trafficking, which makes these cells more susceptible to fendiline. Overall, our data reveal a link between carbapenem resistance and the Lol pathway, which can be leveraged for new drug development.
- Open Access
- 16 July 2024
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 4 (8) , 3125-3134
Screening Privileged Alkyl Guanidinium Motifs under Host-Mimicking Conditions Reveals a Novel Antibiotic with an Unconventional Mode of Action
Screening large molecule libraries against pathogenic bacteria is often challenged by a low hit rate due to limited uptake, underrepresentation of antibiotic structural motifs, and assays that do not resemble the infection conditions. To address these limitations, we present a screen of a focused library of alkyl guanidinium compounds, a structural motif associated with antibiotic activity and enhanced uptake, under host-mimicking infection conditions against a panel of disease-associated bacteria. Several hit molecules were identified with activities against Gram-positive and Gram-negative bacteria, highlighting the fidelity of the general concept. We selected one compound (L15) for in-depth mode of action studies that exhibited bactericidal activity against methicillin-resistant Staphylococcus aureus USA300 with a minimum inhibitory concentration of 1.5 μM. Structure-activity relationship studies confirmed the necessity of the guanidinium motif for antibiotic activity. The mode of action was investigated using affinity-based protein profiling with an L15 probe and identified the signal peptidase IB (SpsB) as the most promising hit. Validation by activity assays, binding site identification, docking, and molecular dynamics simulations demonstrated SpsB activation by L15, a recently described mechanism leading to the dysregulation of protein secretion and cell death. Overall, this study highlights the need for unconventional screening strategies to identify novel antibiotics.
- 16 July 2024
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 4 (8) , 3125-3134
Open AccessScreening Privileged Alkyl Guanidinium Motifs under Host-Mimicking Conditions Reveals a Novel Antibiotic with an Unconventional Mode of Action
Screening large molecule libraries against pathogenic bacteria is often challenged by a low hit rate due to limited uptake, underrepresentation of antibiotic structural motifs, and assays that do not resemble the infection conditions. To address these limitations, we present a screen of a focused library of alkyl guanidinium compounds, a structural motif associated with antibiotic activity and enhanced uptake, under host-mimicking infection conditions against a panel of disease-associated bacteria. Several hit molecules were identified with activities against Gram-positive and Gram-negative bacteria, highlighting the fidelity of the general concept. We selected one compound (L15) for in-depth mode of action studies that exhibited bactericidal activity against methicillin-resistant Staphylococcus aureus USA300 with a minimum inhibitory concentration of 1.5 μM. Structure-activity relationship studies confirmed the necessity of the guanidinium motif for antibiotic activity. The mode of action was investigated using affinity-based protein profiling with an L15 probe and identified the signal peptidase IB (SpsB) as the most promising hit. Validation by activity assays, binding site identification, docking, and molecular dynamics simulations demonstrated SpsB activation by L15, a recently described mechanism leading to the dysregulation of protein secretion and cell death. Overall, this study highlights the need for unconventional screening strategies to identify novel antibiotics.
- Open Access
- 15 July 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (63) , 8272-8275
Synthesis and biological evaluation of vioprolide B and its dehydrobutyrine-glycine analogue
Vioprolide B and an analogue, in which the ( E )-dehydrobutyrine was replaced by glycine, were synthesized and studied in biological assays which revealed cytotoxicity solely for vioprolide B, presumably by covalent binding to the target protein.
- 15 July 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (63) , 8272-8275
Open AccessSynthesis and biological evaluation of vioprolide B and its dehydrobutyrine-glycine analogue
Vioprolide B and an analogue, in which the ( E )-dehydrobutyrine was replaced by glycine, were synthesized and studied in biological assays which revealed cytotoxicity solely for vioprolide B, presumably by covalent binding to the target protein.